Trial Profile
The Effect of a Twice Daily, 200 mg Dose of Oral Fidaxomicin Compared to Placebo on Risk of Acquiring C. Difficile and Developing C. Difficile Infection (CDI) in High Risk Patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2015
Price :
$35
*
At a glance
- Drugs Fidaxomicin (Primary)
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- 19 Jul 2012 Planned initiation date changed from 1 Apr 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 21 Mar 2012 New trial record